An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice

Roche logo

Roche

Status

Completed

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Study type

Observational

Funder types

Industry

Identifiers

NCT01893268
ML28621

Details and patient eligibility

About

This prospective, observational study will assess the effectiveness and safety of Avastin (bevacizumab) as 1st line therapy in elderly patients with advanced non-squamous non-small cell lung cancer in clinical practice. Therapy with Avastin and standard chemotherapy will be administered according to the treating physician. Data will be collected for approximately 4 years.

Enrollment

279 patients

Sex

All

Ages

65+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients, >= 65 years of age
  • Diagnosis of advanced non squamous Non-Small Cell Lung Carcinoma (nsNSCLC, stage IIIB or IV) for whom the physician has decided to initiate a treatment with Avastin combined with chemotherapy as 1st line therapy
  • Having received oral and written information about the study, and having signed a written consent form

Exclusion criteria

  • Participation in a cancer clinical trial with an investigational medicinal product other than this study
  • Patient previously treated with Avastin
  • Patient under supervision or guardianship

Trial design

279 participants in 1 patient group

Cohort

Trial contacts and locations

88

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems